MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.05.009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P3.cr-09 MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma" With "MET Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

OncoTargets and Therapy
OncologyPharmacology
2015English

MET-EGFR Dimerization in Lung Adenocarcinoma Is Dependent on EGFR Mtations and Altered by MET Kinase Inhibition

PLoS ONE
Multidisciplinary
2017English

MET or NRAS Amplification Is an Acquired Resistance Mechanism to the Third-Generation EGFR Inhibitor Naquotinib

Scientific Reports
Multidisciplinary
2018English

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-mutant Non-Small Cell Lung Cancer Cells

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

P063 STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2010English

TBC1D32-RET: A Novel RET Oncogenic Fusion in Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy